Table 1 Patients characteristics by the treatment interval between secondary cytoreductive surgery and adjuvant chemotherapy
|  | Entire cohort (n = 79) | Group 1 (treatment interval ≤ 10 days, n = 42) | Group 2 (treatment interval > 10 days, n = 37) | p value |
|---|---|---|---|---|
Treatment interval, days (range) | 10 (4–86) | 8 (4–10) | 19 (11–86) | <  0.001 |
Median age, yr (range) | 48 (18–69) | 49 (24–44) | 48 (18–69) | 0.613 |
Median CA-125, U/mL (range) | 18.4 (1.5–2446.1) | 26.1 (1.5–685.2) | 15.1 (1.8–2446.1) | 0.190 |
Histology | Â | Â | Â | 0.957 |
 Serous | 60 (75.9%) | 32 (76.2%) | 28 (75.7%) |  |
 Non-serous | 19 (24.1%) | 10 (23.8%) | 9 (24.3%) |  |
Surgery | Â | Â | Â | 0.957 |
 Laparoscopy | 19 (24.1%) | 10 (23.8%) | 9 (24.3%) |  |
 Laparotomy | 60 (75.9%) | 32 (76.2%) | 28 (75.7%) |  |
ASA scorea | Â | Â | Â | 0.798 |
 1 | 17 (21.5%) | 10 (23.8%) | 7 (18.9%) |  |
 2 | 57 (72.2%) | 29 (69.0%) | 28 (75.7%) |  |
 3 | 5 (6.3%) | 3 (7.1%) | 2 (5.4%) |  |
Residual diseaseb | Â | Â | Â | 0.718 |
 R0 | 57 (72.2%) | 29 (69.0%) | 28 (75.7%) |  |
 R1 | 9 (11.4%) | 6 (14.3%) | 3 (8.1%) |  |
 R2 | 13 (16.5%) | 7 (16.7%) | 6 (16.2%) |  |
Platinum free interval | Â | Â | Â | 0.082 |
 6-12mo | 14 (17.7%) | 10 (23.8%) | 4 (10.8%) |  |
 over 12mo | 65 (82.3%) | 32 (76.2%) | 33 (89.2%) |  |
Recurrence no. | Â | Â | Â | 0.243 |
 1st recur | 72 (91.1%) | 40 (95.2%) | 32 (86.5%) |  |
 2nd recur | 7 (8.9%) | 2 (4.8%) | 5 (13.5%) |  |